BRN Discussion Ongoing

TheDrooben

Pretty Pretty Pretty Pretty Good
But was the consolidation tied with a change of domicile and registration on a new exchange?

This is different from a consolidation where the board has kept the boat afloat by issuing more shares, while selling off the klinker boards down to the water level or below.
You can also look at Genetic Technolgies (ASX GTG) a company which I held shares in about 10 years ago but sold out due to personal reasons (luckily)...they were looking at DNA pre-determined Breast Cancer diagnosis.......delisted and went to NASDAQ........diluted and diluted and now bought out for a song. You can also look at Tritium. Not saying this will happen to us............everyone is worried about the Chinese buying companies out cheap.......I worry that the US play even dirtier tactics to get want they want......hence my stance on a dual listing to start with
 
  • Like
  • Love
  • Wow
Reactions: 11 users

7für7

Top 20
Germany SP is up 15% so the market must like the news
Pur guy… you must have a deep shock after this announcements… in Germany we are deep red as well ! It’s still the good old year 2025 Marty…

1740654340235.gif
 
  • Haha
Reactions: 1 users
Pur guy… you must have a deep shock after this announcements… in Germany we are deep red as well ! It’s still the good old year 2025 Marty…

View attachment 78291
Currently 4% down after opening close to 8%, would be surprised if we end up green in a few weeks time 😂
 
  • Haha
Reactions: 1 users

The Pope

Regular
  • Like
  • Haha
Reactions: 2 users

Labsy

Regular
If I were to speculate, perhaps they have secured a deal involving the U.S. military, or big corporate and remaining listed on the ASX would require disclosures that they’d prefer to avoid under its rules..? Lol...

Otherwise such a random timing....
Nailed it ;) That's my hunch.
Big NDA they don't want to risk breaking under our shit asx disclosure rules...
I think this is huge! There is no way we are ready for this unless....... 🤔
Here we go...this will seperate the big boys and girls from the the little cry babies ...
I push my chips all in and CALL !......
Nervous and exciting times ahead.... 🫣🤠🙏
 
  • Like
  • Fire
  • Haha
Reactions: 45 users
You can also look at Genetic Technolgies (ASX GTG) a company which I held shares in about 10 years ago but sold out due to personal reasons (luckily)...they were looking at DNA pre-determined Breast Cancer diagnosis.......delisted and went to NASDAQ........diluted and diluted and now bought out for a song. You can also look at Tritium. Not saying this will happen to us............everyone is worried about the Chinese buying companies out cheap.......I worry that the US play even dirtier tactics to get want they want......hence my stance on a dual listing to start with
I understand why they need to get away from the "cloud" of ASX reporting requirements (in a good way) so can see why a Dual Listing, won't meet their objectives.

My biggest beefs, are that I don't want consolidation, or big dilution.

That seems assured, with a NASDAQ listing.

If it's going to be the New Texas Exchange, the TXSE (which is maybe premonitionarily close to TSEx 😛)
That's potentially, a much, much, much, better outcome.

Maybe initial listing requirements of one USD?..
We have some substantial progress here, a bit of pressure on shorts, get the AUD price comfortably above $1.50, over the next 10 to 12 months..

The Company would be mad, to not take advantage of the listing, to raise additional capital for the home stretch, say 100 to 200 million additional shares, to well and truly shore up finances?

No consolidation and an after listing float of around 2 billion shares.

I'd be happy with that.
 
Last edited:
  • Like
  • Fire
Reactions: 14 users
Nailed it ;) That's my hunch.
Big NDA they don't want to risk breaking under our shit asx disclosure rules...
I think this is huge! There is no way we are ready for this unless....... 🤔
Here we go...this will seperate the big boys and girls from the the little cry babies ...
I push my chips all in and CALL !......
Nervous and exciting times ahead.... 🫣🤠🙏
 
  • Haha
  • Fire
  • Like
Reactions: 5 users

Galaxycar

Regular
I would even go as far as to ask is management actually working for shareholders or ARM, Get the shares on the US Stock market,fail again for 3-6mths sorry shareholders we tried,but luckily ARM has offered you lucky shareholders a shitful price which we the board and our illustrious failure of a CEO of course approve,no ASX,NO government takeover approval required. THEFT another Aussie company stolen by the big boys. Ask yourself have you seen any evidence that the board and management have been working for shareholder.ABSOLUTELY none.
 
  • Like
Reactions: 2 users

The Pope

Regular
I would even go as far as to ask is management actually working for shareholders or ARM, Get the shares on the US Stock market,fail again for 3-6mths sorry shareholders we tried,but luckily ARM has offered you lucky shareholders a shitful price which we the board and our illustrious failure of a CEO of course approve,no ASX,NO government takeover approval required. THEFT another Aussie company stolen by the big boys. Ask yourself have you seen any evidence that the board and management have been working for shareholder.ABSOLUTELY none.
Atleast you are persistent with the negative view points. Common mate, please stop. Anyone who knows where galaxycar lives please go around and give him a hug. Thanks in advance.
 
  • Haha
  • Like
  • Fire
Reactions: 11 users
Atleast you are persistent with the negative view points. Common mate, please stop. Anyone who knows where galaxycar lives please go around and give him a hug. Thanks in advance.
Smells like someone's having an accident in their pants..

Ot Ohhh.. He better not sit down..
 
  • Haha
Reactions: 3 users

Galaxycar

Regular
I dont mind the hugs Pope, But can you honestly say in the last three years where you have thought fuck the board and CEO know what their doing, they are doing a fantastic job.To me this is just another excuse to why they are failing,blaming the ASX now and our disclosure rule, remember those rule are meant and I do laugh,meant to protect shareholders from unscrupulous management and CEO’S they provide the checks and balances, supposedly The very thing our Board and management are saying they need to do, escape these checks and balances. I just hope that shareholders are starting to see that hey they are not working in our best interes.
 
  • Like
Reactions: 2 users

Beebo

Regular
Best news ever!
The ASX has been nothing but poison. BrainChip has high stakes technologies…it deserves a better facility and exchange.

Let’s GO!
 
  • Like
  • Fire
  • Love
Reactions: 31 users

Galaxycar

Regular
Dingo I read one of your posts today didn’t sound as though you were so convinced either this was a good thing.Price is going one way and as I ve said before every time the board or Sean open their mouth the share price goes down. Remember if they take the share to the USA no more AGM’s in Australia no accountability to Australian shareholders try asking them a question then or asking for a explanation
 
  • Like
  • Fire
Reactions: 3 users

JoMo68

Regular
I feel the same regarding uncertainty with freedom to trade. However, could be great timing with the recent US Airforce contract for the US investors to push SP up???
I wonder whether with Trumps US centric plans, BrainChip needs to become a US company to get US contracts (especially sensitive government ones) 🤔
 
  • Like
  • Love
  • Fire
Reactions: 29 users

JoMo68

Regular
I think you might have hit the nail on the head. The US military is obviously very interested in what we've got and our product will be MUCH easier for them to procure if BRN is a US company. Remember who's in the Whitehouse now. Im sure Trump would "convince" the SEC to allow BRN into the market so that Defence can source our unique technology from a US company..............
Snap!! I should have read your post first!
 
  • Like
  • Fire
  • Haha
Reactions: 7 users

Guzzi62

Regular
I will just paste what the company said about moving:

The key reasons influencing this decision are as follows:

1.
The US market is home to the world’s largest technology investment exchange and most of the world’s largest semiconductor and Artificial Intelligence (AI) companies. It provides access to a substantially larger and highly technologically sophisticated pool of potential investors on a global scale. US technology sector investors are generally more familiar with AI technology companies and have a deeper understanding of valuation methodologies for emerging technology companies like BrainChip.

2.
A US listing has the potential to be a positive revaluation and re-pricing catalyst for all existing BRN shareholders, exposing the Company to the possible entry of new US based technology investors, both institutional and retail, who have previously not been able or willing to invest in BrainChip due to company policies prohibiting foreign investment or other compliance related concerns.

3.
SEC disclosure rules provide greater protection for the Company and our customer’s commercially sensitive information, allowing BrainChip to conduct its commercial activities without the risk of being compelled to disclose confidential and commercially sensitive information that breach Non-Disclosure Agreements (NDA) signed with BrainChip’s customers, commercial ecosystem partners, and licensees thus removing a serious obstacle to commercial success.

4.
A simultaneous delisting from the Australian Securities Exchange (ASX) would reduce regulatory compliance, cost and disclosure obligations that exist in a dual-listed scenario. By pursuing a simultaneous US listing and delisting from the ASX, and the cancellation of the quotation on the OTCQX market and the ADR program, the intended result is a clean and simple transition from one exchange to another with minimal cost and without the regulatory and compliance obligations associated with being dual listed.

BrainChip Chairman, Antonio J. Viana said:
“The decision to explore a US listing was taken after considerable reflection and subject to rigorous Board debate and evaluation.
The Board unanimously believes this strategic decision is in the best interests of our shareholders, our employees, our partners and our existing and future licensees. It will elevate BrainChip’s value and profile on the world’s largest, most dynamic and technology-focused investment market.
In the event we move forward with redomiciling, I want to reassure our valued shareholders, the vast majority of whom are Australian retail investors, they will be able to buy, hold and sell shares of our new US parent company without restrictions once the US listing has taken effect.
I am confident this strategic decision is in the best interests and will be a catalyst for value, appreciation, and continued growth for our Company.”
This announcement is authorised for release by the BRN Board of Directors.

So there you have it!

Does it make any sense? Yes to me it does.
 
  • Like
  • Fire
  • Love
Reactions: 35 users

sl.oldi

Member
it would be interesting to know when this will take place...
 
  • Like
Reactions: 1 users

jrp173

Regular
  • Like
  • Haha
Reactions: 9 users
I will just paste what the company said about moving:

The key reasons influencing this decision are as follows:

1.
The US market is home to the world’s largest technology investment exchange and most of the world’s largest semiconductor and Artificial Intelligence (AI) companies. It provides access to a substantially larger and highly technologically sophisticated pool of potential investors on a global scale. US technology sector investors are generally more familiar with AI technology companies and have a deeper understanding of valuation methodologies for emerging technology companies like BrainChip.

2.
A US listing has the potential to be a positive revaluation and re-pricing catalyst for all existing BRN shareholders, exposing the Company to the possible entry of new US based technology investors, both institutional and retail, who have previously not been able or willing to invest in BrainChip due to company policies prohibiting foreign investment or other compliance related concerns.

3.
SEC disclosure rules provide greater protection for the Company and our customer’s commercially sensitive information, allowing BrainChip to conduct its commercial activities without the risk of being compelled to disclose confidential and commercially sensitive information that breach Non-Disclosure Agreements (NDA) signed with BrainChip’s customers, commercial ecosystem partners, and licensees thus removing a serious obstacle to commercial success.

4.
A simultaneous delisting from the Australian Securities Exchange (ASX) would reduce regulatory compliance, cost and disclosure obligations that exist in a dual-listed scenario. By pursuing a simultaneous US listing and delisting from the ASX, and the cancellation of the quotation on the OTCQX market and the ADR program, the intended result is a clean and simple transition from one exchange to another with minimal cost and without the regulatory and compliance obligations associated with being dual listed.

BrainChip Chairman, Antonio J. Viana said:
“The decision to explore a US listing was taken after considerable reflection and subject to rigorous Board debate and evaluation.
The Board unanimously believes this strategic decision is in the best interests of our shareholders, our employees, our partners and our existing and future licensees. It will elevate BrainChip’s value and profile on the world’s largest, most dynamic and technology-focused investment market.
In the event we move forward with redomiciling, I want to reassure our valued shareholders, the vast majority of whom are Australian retail investors, they will be able to buy, hold and sell shares of our new US parent company without restrictions once the US listing has taken effect.
I am confident this strategic decision is in the best interests and will be a catalyst for value, appreciation, and continued growth for our Company.”
This announcement is authorised for release by the BRN Board of Directors.

So there you have it!

Does it make any sense? Yes to me it does.
What the below statement by Viana says to me is that BRN, as it is currently, will not be the entity we will be invested in directly.

It indicates that the company plans to create a new "parent" entity that I expect will control BRN as a subsidiary (like India) and all its assets etc.

I suspect the current BRN SH equity would be transferred to or purchased by the new parent entity of which we will be SHs. Just my thoughts anyway.

"able to buy, hold and sell shares of "our new US parent company"

Now, whether that makes it easier to list a newly created entity, we'll see...maybe. If so, and once listed, then BRN merely gets delisted on the ASX and falls under the control of the new parent entity.

Something like this may fall under the realm of the SPAC path imo. Which is essentially a back door listing to a US exchange.

Preliminary glance indicates de-SPACing may be primarily private companies as targets though this 2021 article by Herbert Smith Frehills solicitors speaks of Aust company targets, not stating either ASX listed or private being a requirement.

Worth a read to understand how it works. I looked into this process a few years ago with another company I was invested in and just reaquainting myself again, just in case.


31 Mar 2021 Insight Australia
Article - By Tom O’Neill, Tony Damian, Nicole Pedler and Henry Simpson

In 2020, SPACs overtook traditional IPOs in the US by number and each of them will need to find acquisition targets or be liquidated within a set time frame. Increasingly, Australian companies are on the radar as acquisition targets for SPACs. In this article we examine what they are, why Australian SPACs are less likely to emerge and the key considerations for Australian businesses being acquired by a SPAC as an alternative to a private sale or going public through an IPO.

In brief​

  • A special purpose acquisition company (SPAC) is a newly formed company with no assets or operations that raises initial capital in an IPO (most commonly in a US public offering) with the purpose of finding an operating company to buy with the proceeds of the raise and any subsequent raise at the time of the acquisition (a process known as ‘de-SPACing’).
  • SPACs are not currently able to list on the ASX due to its rules against cash-box companies and it would take a sizeable policy shift for this situation to change.
  • Acquisition by a SPAC is in substance a back-door listing for the acquisition target, which means targets of SPACs need to be in effect IPO and listing ready and prepared to meet foreign (usually US) governance and regulatory requirements.

What are SPACs?​

A special purpose acquisition company (SPAC) is an entity, sometimes referred to as a ‘shell company’, with no business of its own which raises initial capital and becomes publicly listed with the purpose of finding an operating company to buy within a set time frame – usually 24 months with the possibility of an extension - using the proceeds of the capital raising. The process of the listed SPAC acquiring its target company is known as ‘de-SPACing’. SPACs in the United States will usually raise additional capital at the time of the de-SPAC in an equity offering commonly called a ‘PIPE’ transaction to finance both the cost of the acquisition beyond the initial raise as well the redemptions in cash available at the time of the de-SPAC to shareholders of their initial investments in the IPO.
There are few parameters on a SPAC in that it may or may not specify in its prospectus a particular type of industry or geographic focus for its acquisitions. The investment thesis and attractiveness of the SPAC to investors in the IPO is a function both of the target industry and geographic focus as well as the strength and track record of the sponsor/management team. However, it must identify its target to acquire within a specified time frame, which is typically around 24 months and subject to extension. If SPACs do not complete their acquisition before their specified deadline, or in the case of a US regulated SPAC within three years of completing its IPO, they must liquidate and return the capital raised on listing plus interest. To compensate for the illiquidity and lack of returns prior to the acquisition completing, SPACs will commonly employ mechanisms such as the issue of units of common stock and warrants with differential pricing which trade separately. The sponsor of the SPAC will typically receive around 20% of the SPAC’s common stock as well as management fees following the de-SPACing.
SPACs have surged in popularity in the US$83 billion of capital was raised by US listed SPACs in 2020 (a 513% increase from 2019),1 and the capital raised by US SPAC listings so far in 2021 has already exceeded that amount.2 US listed SPAC IPOs accounted for more than half of the overall US listed IPOs in 2020. In terms of the increase, whilst there were 59 SPAC offerings in the US in 2019, in 2020 there were 248, representing a 320% increase.3
Whilst traditionally a US structure, in Europe SPACs are rising in popularity. For example, in 2020 Herbert Smith Freehills advised Morgan Stanley and UBS as joint global co-ordinators and joint bookrunners on the English/US aspects of the US$340 million IPO of EverArc Holdings Limited, a British Virgin Islands-organised SPAC and its standard listing on the London Stock Exchange. Although only 4 SPACs were listed in the UK in 2020,4 the UK Listing Review (a review commissioned by the Chancellor of the Exchequer to review the UK listing process) recommended in March 2021 that existing listing rules should be relaxed to encourage an increase in UK listed SPACs. In the meantime, there has been a very substantial surge in European SPACs listed on Euronext Amsterdam, which has succeeded in capturing much of the European demand in view of its flexible regulatory structure and ability to assimilate into deal structures many of the US SPAC features that have not historically been part of UK SPAC practice. Herbert Smith Freehills is currently working on several ongoing SPAC listings in Amsterdam.

Considerations for Australian targets​

It would require a sizable policy shift on behalf of ASIC and ASX to allow for the IPO of a SPAC in Australia due to existing restrictions under the ASX Listing Rules on 'cash box' entities, back door listings and the ASX’s view on the appropriate structure and operations of a listed entity.
Nonetheless, with approximately US$83 billion raised via US SPAC listings in 2020, and that figure having already been surpassed by 2021 US SPAC listings, the emergence of a more active market in Europe and the substantial interest of other global stock exchanges in the SPAC product, it seems only a matter of time before Australian companies are identified as the targets for a merger or acquisition by a SPAC. In the near term this is overwhelmingly likely to involve US SPACs contemplating backdoor listings of Australian targets on a US stock exchange, however bidders will increasingly be listed in other jurisdictions. We are already seeing entities in Australia considering whether they might be appropriate SPAC targets and what this means for them compared to an IPO or another form of sale.
Recently, the prospectus of Catcha Investment Corporation, a SPAC listed on the NYSE in February 2021 stated that it would focus its search for a target in the Australian and Southeast Asian technology sector.
As the de-SPAC process is a form of backdoor listing, Australian companies should be keenly aware about what an acquisition by a SPAC on a foreign exchange would mean for them.
Key considerations include:
  • Timing: In the US, a de-SPAC takes on average around three to five months from announcement to completion (which is faster than a traditional US listing). Additionally, as the target of a SPAC, a company will not have the same time to internally consider their readiness for, and the implications of, listing they would otherwise have during a traditional IPO process even though the backdoor listing will necessitate many of the same disclosure and regulatory requirements of an IPO. The target will also not have the level of control over the process as it would in an ordinary IPO. None of this is should carry negative implications – rather prospective SPAC targets should proactively assess and develop their IPO readiness ahead of an approach.
  • Pricing: Importantly, SPAC targets may often achieve through negotiations akin to a traditional M&A process greater certainty on pricing than is the case with a traditional IPO, which sellers may consider a substantial benefit particularly in a volatile pricing environment.
  • Becoming a listed company: A lot of work is involved in ensuring the target is ready for listing, including ensuring its Board composition, corporate governance, disclosure processes, and accounts will need to meet the necessary requirements initially and on an ongoing basis. The short time for the execution of the de-SPACing transaction means that the target should already be, or will need to swiftly adopt, the governance, Board and disclosures of a listed entity. The SPAC target must also be ready to comply with the ongoing reporting and governance obligations of the jurisdiction of the listing, which to date has been overwhelmingly the United States but will increasingly include other jurisdictions.
  • Prospectus level disclosures: The target company will be required by the regulatory body governing the foreign exchange or local securities laws to provide information similar to that required if they were listed via a normal IPO procedure. Some of the key disclosures are:
    • the terms of the de-SPAC transaction;
    • a description of the target and its management, directors and governance structure;
    • a description of the target’s business as well as valuation and projections;
    • the audited financial statements of the SPAC and the target for the relevant track record period. All financial statements and information will need to be prepared under the required auditing standard;
    • unaudited interim financial statements if required based on the date of the most recent financial statements;
    • unaudited pro forma financial information reflecting the proposed acquisition;
    • management’s discussion and analysis for the SPAC and the target; and
    • a description of the risk factors associated with the de-SPAC.
  • SPAC shareholder approval: In the US (and in the Netherlands but not in the UK (yet)), there is typically a requirement that the public stockholders of a SPAC must approve by a majority of votes the de-SPACing transaction.
  • Redemption rights: In the US (and in the Netherlands but not in the UK (yet)), public stockholders have the right to redeem their public shares for a pro rata proportion of the proceeds of the IPO. It is also common to see sponsors and their directors enter into a letter agreement pursuant to which they agree to waive their redemption rights. There is little recourse for the target of the de-SPACing transaction if the deal does not go through.
With their meteoric rise in the US and rapid acceptance in other jurisdictions, SPACs should be seen as an exciting new opportunity for Australian companies. Nonetheless, the prospect of listing on a foreign exchange will come with its own unique considerations, so Australian targets need to understand and be prepared for their involvement in a de-SPACing transaction.
 
  • Like
  • Thinking
  • Love
Reactions: 24 users
Top Bottom